Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT05078580
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: Piqray Prescriber's/HCP guide for hyperglycemia
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05073120
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
Phase 4
Completed
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Genetic: OAV101
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT05073133
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
Completed
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Other: All participants
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18457
- Registration Number
- NCT05066685
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
Phase 3
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: LOU064
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT05048342
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Completed
- Conditions
- Post-essential Thrombocythemia MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis
- Interventions
- Other: Jakavi
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1012
- Registration Number
- NCT05044026
- Locations
- 🇩🇪
Novartis Investigative Site, Aachen, Germany
Managed Access Programs for LEE011, Ribociclib
- Conditions
- Breast Cancer
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05038631
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT05038735
- Locations
- 🇪🇸
Novartis Investigative Site, Zaragoza, Spain
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9457
- Registration Number
- NCT05037396
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
Study of Efficacy and Safety of ABO809 in Healthy Participants
Phase 1
Completed
- Conditions
- Cryptosporidium Infection, Cryptosporidiosis
- Interventions
- Biological: Cryptosporidium parvum oocysts (ABO809)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05036668
- Locations
- 🇺🇸
Novartis Investigative Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath